Caribou Biosciences (NASDAQ:CRBU) vs. Sutro Biopharma (NASDAQ:STRO) Financial Analysis

Sutro Biopharma (NASDAQ:STROGet Free Report) and Caribou Biosciences (NASDAQ:CRBUGet Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Valuation and Earnings

This table compares Sutro Biopharma and Caribou Biosciences”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sutro Biopharma $153.73 million 2.34 -$106.79 million ($1.83) -2.39
Caribou Biosciences $33.11 million 7.31 -$102.07 million ($1.65) -1.62

Caribou Biosciences has lower revenue, but higher earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sutro Biopharma and Caribou Biosciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sutro Biopharma 0 0 8 0 3.00
Caribou Biosciences 0 0 3 0 3.00

Sutro Biopharma currently has a consensus price target of $12.13, suggesting a potential upside of 176.83%. Caribou Biosciences has a consensus price target of $11.25, suggesting a potential upside of 319.78%. Given Caribou Biosciences’ higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than Sutro Biopharma.

Profitability

This table compares Sutro Biopharma and Caribou Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sutro Biopharma -73.48% -102.06% -29.12%
Caribou Biosciences -372.78% -34.76% -29.58%

Institutional & Insider Ownership

97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 5.9% of Sutro Biopharma shares are held by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Sutro Biopharma has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500.

Summary

Caribou Biosciences beats Sutro Biopharma on 8 of the 13 factors compared between the two stocks.

About Sutro Biopharma

(Get Free Report)

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

About Caribou Biosciences

(Get Free Report)

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.